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Abstract  47 
Background: The main aim of specific immunotherapy is sustained effect due to changes in the 48 
immune system that can only be demonstrated in long-term trials.  49 
Objective: To investigate sustained efficacy and disease-modification in a 5 year double-blind, 50 
placebo-controlled trial, including 2 years of blinded follow-up after completion of a 3-year period 51 
of treatment, with the SQ-standardized grass allergy immunotherapy tablet (AIT), Grazax® (Phleum 52 
pratense 75,000 SQ-T/2,800 BAU1, ALK, Denmark) or placebo. 53 
Methods: A randomized, double-blind, placebo-controlled, multinational, phase III trial including 54 
adults with a history of moderate-severe grass pollen induced allergic rhinoconjunctivitis, with or 55 
without asthma, inadequately controlled by symptomatic medications. 238 participants completed 56 
the trial. Endpoints included rhinoconjunctivitis symptom and medication scores, combined scores, 57 
asthma symptom and medication scores, quality of life, days with severe symptoms, immunological 58 
endpoints, and safety parameters. 59 
Results: The mean rhinoconjunctivitis daily symptom score was reduced by 25-36% (p≤0.004) in 60 
the grass AIT group compared to the placebo group over the 5 grass pollen seasons covered by the 61 
trial. The rhinoconjunctivitis daily medication score was reduced by 20-45% (p≤0.022 for seasons 62 
1-4; p=0.114 for season 5) and the weighted rhinoconjunctivitis combined score were reduced by 63 
27-41% (p≤0.003) in favor of active treatment. The percentage of days with severe symptoms 64 
during the peak grass pollen exposure was in all seasons lower in the active group than in the 65 
placebo group, with relative differences of 49-63% (p≤0.0001). Efficacy was supported by long-66 
lasting significant effects on the allergen-specific antibody response. No safety issues were 67 
identified. 68 
                                                 
1SQ-T (standardized quality tablet units) and BAU (biological activity units) are quantitative measures of biological 
activity; i.e. the potency of allergen extracts/vaccines. One grass AIT contains 75,000 SQ-T of Timothy (Phleum 
pratense) grass pollen extract (measure of total biological potency using ALK in-house reference), equivalent to 2,800 
BAU (measure of total biological potency, defined by the FDA). 
Durham, page 4 
Conclusion: The results confirm disease-modification by SQ-standardized grass AIT in addition to 69 
effective symptomatic treatment of allergic rhinoconjunctivitis. 70 
 71 
Clinical implications 72 
Grass allergy immunotherapy tablet treatment has sustained, disease-modifying efficacy 2 years 73 
after completion of treatment and represents an important treatment option in grass allergy 74 
inadequately controlled by symptomatic medications. 75 
 76 
Capsule summary 77 
The first report of a full 5-year randomized, placebo-controlled trial of grass allergy immunotherapy 78 
tablet for seasonal allergic rhinitis, confirming effective symptom control and disease-modification 79 
2 years after completion of 3 year’s treatment. 80 
 81 
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Introduction 91 
The increasing prevalence of atopic diseases such as allergic rhinitis/rhinoconjunctivitis, allergic 92 
asthma, and food allergy is a major health issue worldwide. In Western Europe and the US up to 93 
20% of the adult population suffers from allergic rhinoconjunctivitis(1-3). Indirect costs such as 94 
absenteeism from work and decreased productivity are substantial; estimates suggest 3.5 million 95 
lost workdays per year in the US alone(4). 96 
 97 
The main aim of specific immunotherapy is a sustained significant and clinically relevant disease-98 
modifying effect in post treatment years(5). Changes in T-cell reactivity and induction of non-IgE 99 
antibodies with blocking capacity are regarded as immunological markers of the 100 
immunomodulation that leads to clinical tolerance(6;7). 101 
 102 
It is generally accepted that the appropriate primary endpoints for assessing the response of allergic 103 
rhinoconjunctivitis to specific immunotherapy are the rhinoconjunctivitis symptom and medication 104 
scores, which may be reported separately or in a combined score. Because both symptom and 105 
medication scores are reduced by effective treatment of allergic rhinoconjunctivitis, it is now 106 
considered advantageous by global regulatory bodies to report the 2 responses in a single combined 107 
score(5;8;9).  108 
 109 
The SQ-standardized grass allergy immunotherapy tablet (AIT) contains an extract of Phleum 110 
pratense (Timothy grass) pollen. The grass AIT is indicated and approved in most of Europe for 111 
disease-modifying treatment of grass pollen induced rhinitis and conjunctivitis in adults and 112 
children. The tolerability and efficacy of the tablet has been demonstrated in several randomized, 113 
placebo-controlled trials in Europe and North America(10-16).  114 
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 115 
This is the first full 5-year double-blind, placebo-controlled trial demonstrating efficacy of 116 
sublingual tablet immunotherapy with 3 years of treatment and 2 years of immunotherapy-free 117 
follow-up after completion of treatment. Symptomatic medications were provided to all participants 118 
as needed throughout the trial. 119 
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Methods 120 
Clinical trial design 121 
Details of the randomized, double-blind, placebo-controlled trial, conducted according to the 122 
Declaration of Helsinki(17), have been published previously(11;12;14) (ClinicalTrials.gov number: 123 
NCT00227279). From original 1 year of treatment, the trial was extended to cover in total 3 years 124 
of active treatment and 2 years of follow-up to investigate long-term and sustained efficacy of grass 125 
AIT (extension implemented in April 2005). The ethics committees in each country approved the 126 
trial as well as the extension, and participants gave written informed consent and re-consented to the 127 
extension prior to its inception. Enrollment of participants commenced in September 2004. A total 128 
of 51 sites in 8 European countries participated in the trial. Data collection, management, statistics 129 
and results reporting upon trial completion were performed by the sponsor. 130 
 131 
Trial population 132 
The main inclusion criteria were: males or females; aged 18-65 years; a clinical history of grass 133 
pollen induced allergic rhinoconjunctivitis of 2 years or more requiring treatment during the grass 134 
pollen season, with rhinoconjunctivitis symptoms interfering with usual daily activities or sleep and 135 
remaining troublesome despite treatment with symptomatic medications; and positive skin prick test 136 
(wheal diameter ≥3 mm) and serum specific IgE (IgE CAP class ≥2) to Phleum pratense. The main 137 
exclusion criteria were: FEV1<70% of predicted value; a clinical history of symptomatic seasonal 138 
allergic rhinitis/asthma due to tree or weed pollen potentially overlapping the grass pollen season; a 139 
clinical history of significant active perennial allergic rhinitis/asthma caused by an allergen to 140 
which the participant was regularly exposed; previous immunotherapy within the last 5 years; and a 141 
history of anaphylaxis or angioedema. 142 
 143 
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Assignment and treatment 144 
Block randomization, randomly assigned participants to daily treatment with grass AIT (Grazax®, 145 
Phleum pratense 75,000 SQ-T/2,800 BAU, ALK, Denmark) or placebo (1:1). Randomization was 146 
performed by ALK (by a statistician not otherwise involved in the trial) using the SAS® system for 147 
Windows (version 8e).  148 
 149 
The tablets were supplied as fast-dissolving, neutral-tasting oral lyophilisates for sublingual 150 
application. Excipients included gelatin, mannitol and sodium hydroxide. Placebo was 151 
indistinguishable from the active tablet in appearance but contained no grass pollen extract. 152 
Investigational treatment was initiated 4-8 months prior to the anticipated start of the grass pollen 153 
season 2005 and per the extension continued in a double-blinded manner until the end of the season 154 
2007. The additional 2 years of follow-up without investigational treatment was continuously 155 
doubled-blinded. During each grass pollen season, all participants had free access to open-labeled 156 
symptomatic medications in case of rhinoconjunctivitis or asthma symptoms. The participants 157 
attended the clinics at least twice a year; 2 weeks before the anticipated start and 1 week after the 158 
grass pollen season. 159 
 160 
Grass pollen season 161 
Grass pollen counts were obtained from regional pollen stations in each country. The season was 162 
defined with start as the first day of 3 consecutive days with grass pollen count ≥10 grains/m3, and 163 
stop as the last day in the last occurrence of 3 consecutive days with pollen count >10 grains/m3. 164 
The peak pollen season was defined as the 15 days period with the highest average pollen count. 165 
Cumulated pollen loads were calculated after 3 and 10 weeks of each season. 166 
 167 
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Outcomes 168 
The main objective was to evaluate sustained efficacy 2 years after completion of a 3-year period 169 
with active treatment compared to placebo. The ranked co-primary endpoints each year were 170 
average rhinoconjunctivitis daily symptom score (DSS) and rhinoconjunctivitis daily medication 171 
scores (DMS) within the grass pollen seasons. The scores were registered daily from the pre-172 
seasonal visit and until the post-seasonal visit in an electronic diary (LogPad, PHT Corporation, 173 
Charlestown, US). A weighted rhinoconjunctivitis combined score (RCS) was calculated based on 174 
the primary endpoints (please refer to the Online Repository at www.JACIonline.org for details). 175 
 176 
Further secondary endpoints included rhinoconjunctivitis quality of life(18) during the peak grass 177 
pollen seasons, percentages days with severe symptoms (defined as a symptom score of 3 in any of 178 
the 6 rhinoconjunctivitis symptoms), change from baseline in specific IgG4 and IgE-blocking factor 179 
(i.e. the presence of components blocking IgE-allergen binding); change from baseline in facilitated 180 
allergen presentation (FAP) inhibition (for details on immunological methods: see Online 181 
Repository at www.JACIonline.org), and safety and tolerability (adverse events, serum and urine 182 
safety parameters).  183 
 184 
Asthma DSS and asthma DMS were analyzed in the subgroup of participants having asthma at 185 
randomization (see Online Repository at www.JACIonline.org for details). Post hoc the asthma 186 
combined score was calculated based on the same principle as the RCS.  187 
 188 
Statistics 189 
The sample size calculation applied to the first year analysis(11) and no formal power calculation 190 
was performed for the extension. Pre-specified data analysis was carried out based on the full 191 
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analysis set according to the statistical analysis plan (prepared before unblinding). No imputation of 192 
data was done in case of missing data and all available data was used to its full extent. Due to a 193 
prospective hierarchical ranking of primary and key secondary endpoints, no adjustments for 194 
multiplicity were applied. All endpoints were tested on a 5% significance level and all tests and 195 
confidence intervals were 2-sided. The null hypothesis was no difference between the 2 treatment 196 
groups. 197 
 198 
For the co-primary endpoints (1: rhinoconjunctivitis DSS and 2: rhinoconjunctivitis DMS), the 199 
comparison of the 2 treatment groups was done via a generalized linear mixed model. The response 200 
variable per participant was the average rhinoconjunctivitis DSS or DMS for the entire grass pollen 201 
season. Treatment group was included as a fixed effect. Centre and pollen region were aggregated 202 
to country and included as random effect to adjust for variation due to differences in exposure and 203 
possible centre effects. Furthermore, estimates were adjusted for different error variation for each 204 
treatment group. The residuals were assumed to be normally distributed. 205 
 206 
The RCS for the entire season for all 5 years was analyzed using a repeated measurement model 207 
with treatment group and a treatment:year interaction as fixed effects. Participant was included as 208 
random effect. Confidence intervals for the percentage difference relative to placebo for the 209 
adjusted means and medians were found by bootstrapping (Nresamples=10,000). 210 
 211 
For details on the methodology for the additional analyses, please refer to the Online Repository at 212 
www.JACI.org. 213 
 214 
Durham, page 11 
Calculations were performed with the use of SAS statistical software, version 9.2 (SAS Institute, 215 
North Carolina, US) and TIBCO Spotfire S+® 8.1 for Windows (TIBCO Software Inc., Palo Alto, 216 
US).217 
Durham, page 12 
Results 218 
Efficacy 219 
At randomization 634 participants were included in the trial (316 active, 318 placebo). 546 220 
participants completed the first season of the trial. When the trial was extended with another 4 221 
years, 195 participants chose not to enroll or were not offered enrolment due to closure of sites. 222 
Thus, 351 participants continued in the extension (189 active, 162 placebo). These participants were 223 
a representative subset of the population originally included in the trial (see Dahl et al.(12)). 238 224 
participants (135 active, 103 placebo) completed the total 5 years of the trial. A complete 225 
participant disposition during the 5 years of the trial is shown in Figure E1 in the Online Repository 226 
(www.jacionline.org).  227 
 228 
Overall demographics were similar between the 2 treatment groups (please refer to the Online 229 
Repository for more details).  230 
 231 
The mean rhinoconjunctivitis DSS in each season was reduced by 25-36% in the grass AIT group 232 
relative to the placebo group over the 5 grass pollen seasons covered by the trial (Table 1). The 233 
rhinoconjunctivitis DMS in each season was reduced by 20-45% (Table 1).  234 
 235 
The RCS was reduced by 27-41% relative to placebo in the 5 grass pollen seasons (see Figure 1). 236 
The treatment effect was significant for all 5 years of the trial (p<0.01 for all years), with a 237 
statistically insignificant interaction between treatment and year (p=0.60), meaning that the efficacy 238 
in terms of the RCS was similar during the 3 treatment seasons and 2 follow-up seasons. The 239 
average treatment effect over the 5 seasons was 33% (CI95% [30%; 38%]) (see Figure 1). The 240 
corresponding median value for the average treatment effect was 37% (CI95% [30%; 42%]). 241 
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Different approaches to combine the rhinoconjunctivitis DSS and DMS all resulted in statistically 242 
significant reductions in the 2nd follow-up year in favor of grass AIT treatment (data not shown). 243 
 244 
The RCS was dependent on the exposure to grass pollen, and with a steeper increase for the placebo 245 
group than the active group (see Figure 2). The difference between the grass AIT and the placebo 246 
group increased with increasing grass pollen counts.  247 
 248 
The grass pollen seasons varied considerably over the 5 years of the trial, with a significantly lower 249 
grass pollen exposure during the 2nd follow-up season (see Figure 3A). The median grass pollen 250 
exposure in the 2nd follow-up season was 38% lower than in the 1st treatment season and 30% lower 251 
than in the 1st follow-up season and the cumulative exposure during the first 3 weeks of the season 252 
30% and 39% lower, respectively. Interestingly, the relative treatment effect on the RCS during the 253 
5 seasons covered by the trial was highly correlated to the cumulative pollen exposure in the 254 
beginning of the season (see Figure 3B). 255 
 256 
The percentage of days with severe symptoms during the peak grass pollen season was, in all 257 
seasons covered by the trial, lower in the active group than in the placebo group with relative 258 
differences of 49-63% (Table 2). The risk of having days with severe symptoms during the peak 259 
season was 2-3 times lower in the grass AIT group than in the placebo group (odds ratios of 0.47-260 
0.34; Table 2). The participants quality of life, investigated by means of the RQLQ(18), was 261 
significantly improved by active treatment (relative differences of 25-32%; Table 2). 262 
 263 
The relation between numbers of days with severe symptoms per week and the reported weekly 264 
RQLQ was investigated. For all participants and all seasons there was a good agreement, i.e. 265 
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whether in the active group or in the placebo group, the more days with severe symptoms during a 266 
week were reflected in a worse quality of life score during that week (see Figure 4, -∆-). The risk 267 
(odds ratio) of having one or more days with severe symptoms in the active group was significantly 268 
lower than in the placebo group (see Figure 4, -●-).  269 
 270 
The weighted asthma combined score for participants with grass pollen induced asthma at inclusion 271 
(Nactive=79; Nplacebo=72) was reduced by 39% in the active group relative to placebo over the entire 272 
grass pollen seasons (p=0.049) and by 44% over the peak seasons (p=0.030), when combining all 5 273 
years.  274 
 275 
Immunological changes were assessed by means of difference between active and placebo in 276 
change from baseline of specific IgG4, specific IgE-blocking factor and FAP inhibition. The 277 
differences between grass AIT and placebo were significant at all assessments, i.e. p<0.05 (see 278 
Figure 5) and with sustained significant treatment effects at both 1 and 2 years after completion of 279 
the 3 years of treatment. 280 
 281 
Safety and tolerability 282 
No safety issues in relation to the trial treatment were reported. However, the treatment did cause 283 
local application site related adverse events. The 4 most common adverse events were oral pruritus 284 
(reported by 44% from the grass AIT group, 4% from the placebo group), mouth edema (19% grass 285 
AIT, 1% placebo), throat irritation (13% grass AIT, 2% placebo), and ear pruritus (12% grass AIT, 286 
1% placebo). The majority of these events occurred in the active group, was primarily mild in 287 
severity, and had causality most often assessed as related to treatment. Remarkably, the local events 288 
occurring in the placebo group were also commonly assessed as related to treatment. The onset of 289 
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the common local adverse events in the active group was largely on the first or second day of 290 
treatment (see Figure 6: “1 day” and “2 days”), and duration was short (typically for 5-10 min after 291 
tablet intake for 2-8 weeks).  292 
 293 
No treatment-related serious adverse events or events of severe systemic allergic reactions were 294 
reported during the 5 years of the trial. A total of 41 adverse events led to trial discontinuation for 295 
29 participants (18 active, 11 placebo including 1 death). In the grass AIT group 93% of the events 296 
leading to discontinuation were assessed as treatment-related, whereas in the placebo group 35% 297 
were assessed as treatment-related (for more details see Table E2 in the Online Repository). 298 
 299 
No safety issues were detected in lung function assessments, physical examinations, vital signs or 300 
safety laboratory analyses.  301 
302 
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Discussion 303 
This is the first full 5-year, double-blind, multinational, placebo-controlled trial showing sustained 304 
clinical efficacy and disease-modification 2 years after completion of 3 years of treatment with 305 
grass AIT. The 2nd follow-up and final year of this trial showed a statistically significant and 306 
clinically relevant sustained efficacy on the rhinoconjunctivitis symptom score of 25% (p=0.004) in 307 
the active group relative to placebo. This sustained efficacy was observed in the face of the lowest 308 
annual cumulative pollen counts observed during the 5 years of the trial, a circumstance known to 309 
compromise the ability to detect a significant seasonal treatment effect. The significant reduction in 310 
symptoms was accompanied by less use of symptomatic medications. The lack of a statistically 311 
significant difference for the medication score during the 2nd follow-up season was probably a 312 
consequence of both the low pollen exposure and the reduced sample size. A significant reduction 313 
in RCS was obtained during the 5th season, with an average reduction in RCS of 33%, CI95% [30%; 314 
38%] over the 5 years of the trial. The clinical efficacy of the grass AIT has recently been 315 
confirmed in North American populations(15;16).  316 
 317 
The levels of rhinoconjunctivitis symptoms and the use of symptomatic medications rely on grass 318 
pollen exposure. Even if having severe pollen allergy, participants will experience days with no or 319 
only mild symptoms alternating with days with severe symptoms as the pollen exposure varies(19). 320 
In this trial, large day-to-day as well as year-to-year variation in the grass pollen counts were 321 
observed within each pollen region(20), causing corresponding variations in the level of symptoms 322 
and use of symptomatic medications. It has recently been suggested that data could be normalized 323 
for the peak 2 weeks of pollen season to adjust for seasonal and geographical variability in pollen 324 
counts(8). However, this was not done for any of the efficacy analyses in the present trial. 325 
 326 
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There was a significant correlation between the RCS and the cumulative grass pollen counts in the 327 
beginning of the season, which highlights the significant dependency on pollen exposure to be able 328 
to measure efficacy in this type of trials. The correlation may relate to cumulated pollen counts as 329 
reported here, as well as intensity (i.e. maximum peak height) or onset pattern (i.e. how abrupt the 330 
onset of the pollen season is). Also the potency of the pollen grains, the release of lipid mediators 331 
and enhanced allergenicity caused by an interaction with air pollution(21-23) may influence the level 332 
of symptoms and thereby the efficacy measures.  333 
 334 
Days with severe symptoms are by definition the most troublesome days where rhinoconjunctivitis 335 
symptoms exacerbate and significantly impact the participants’ daily life; a fact that is highlighted 336 
by the correlation with the rhinoconjunctivitis quality of life scores. The significant decrease in days 337 
with severe symptoms and the improved quality of life in the grass AIT group both during the 3 338 
treatment seasons and during the 2 follow-up seasons support the clinical relevance of the primary 339 
efficacy endpoints and emphasize that the effect of grass AIT treatment is relevant from the patient 340 
perspective. 341 
 342 
The number of participants symptomatic to other allergens than grass was not systematically 343 
collected. Given the successful randomization on subject characteristics and the equal distribution 344 
of other sensitizations, it is likely that the distribution of poly-allergic subjects was equal between 345 
groups. The efficacy of grass AIT was similar in mono-and poly sensitized participants. There were 346 
no differences between groups in terms of new sensitizations. The preventive effect of 347 
immunotherapy suggested from other trials(24-27) relates to pediatric studies where the rate of new 348 
sensitizations is higher. It remains to be determined whether grass AIT may similarly reduce new 349 
sensitizations. 350 
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 351 
As a post hoc analysis, the asthma combined score was investigated. The significant effect of grass 352 
AIT on asthma supports the united airway disease hypothesis(28;29). A trial is currently ongoing to 353 
assess if grass AIT can also reduce the risk of developing asthma in children(30). 354 
 355 
Clinical efficacy following sublingual grass AIT treatment was associated with sustained increases 356 
in serum grass pollen allergen-specific IgG4 antibodies, accompanied by parallel increases in serum 357 
IgE-blocking factor and in serum inhibitory activity for binding of allergen-IgE complexes to B 358 
cells. Importantly, the immunological changes were sustained 2 years after completion of treatment, 359 
like the observed clinical improvement, and entirely consistent with long-term disease-modification. 360 
The findings are furthermore in agreement with those observed after end of long-term subcutaneous 361 
immunotherapy(7), with the exception that after completion of grass AIT, the sustained increases in 362 
serum IgG4 closely paralleled the increased serum blocking activity whereas after subcutaneous 363 
treatment, IgG4 levels returned 80% towards baseline levels. This suggests that local regulatory 364 
mechanisms involving T-B cell interactions following sublingual application of allergen(31;32) may 365 
result in a greater proportion of IgG4 with high avidity and hence ability to compete with IgE as 366 
compared to the subcutaneous route, where allergen is administered remote from the target organ, 367 
possibly resulting in B cells producing a broader range of both high and low avidity IgG4, with only 368 
the ‘functional’ high avidity IgG4 persisting long-term. 369 
 370 
Conclusions 371 
The sustained, significant and clinically relevant efficacy of the SQ-standardized grass AIT during 2 372 
follow-up seasons and the parallel immunological changes confirms disease-modification; the one 373 
distinct feature separating specific immunotherapy from all other treatment options for allergy. No 374 
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safety issues were identified during the 3 years of treatment or the 2 follow-up years. Specifically, 375 
there were no events of anaphylaxis.  The most common adverse events were mild to moderate 376 
local application site reactions that in most cases presented at treatment initiation. 377 
 378 
In this trial, placebo participants were at all times more likely to have weeks containing days with 379 
severe symptoms during the pollen season compared to the grass AIT group. The number of days 380 
with severe symptoms was directly reflected in a worse quality of life. The significant decrease in 381 
days with severe symptoms and the improved quality of life in the active group support the clinical 382 
relevance of the primary efficacy endpoints and emphasize the relevance of grass AIT treatment 383 
from the patient perspective. 384 
 385 
Thus, the grass AIT should be considered an important treatment option in patients with grass 386 
pollen induced rhinoconjunctivitis who remain uncontrolled on symptomatic medications. 387 
388 
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Tables 503 
Table 1: Rhinoconjunctivitis symptom and medication scores during the 5 grass pollen seasons covered by the trial 504 
 Original Trial Extension Trial†





N*(Grass AIT) 282 172 160 142 137
N*(Placebo) 286 144 127 115 104
Rhinoconjunctivitis Symptom Score
Grass AIT: mean¤ (median) 2.9 (2.6) 2.4 (1.9) 2.6 (2.0) 2.7 (2.3) 2.6 (2.2) 
Placebo: mean (median) 4.1 (3.8) 3.8 (3.5) 3.6 (3.2) 3.6 (3.3) 3.4 (3.2) 
Difference in means         
  Absolute [CI 95%] 1.3 [0.9; 1.7] 1.4 [0.9; 1.9] 1.0 [0.5; 1.6] 0.9 [0.4; 1.5] 0.8 [0.3; 1.4]
  Relative to placebo 31% 36% 29% 26% 25%
  p-value <0.0001 <0.0001 <0.001 <0.001 0.004
Difference in medians      
  Absolute 1.2 1.5 1.2 1.0 1.0
  Relative to placebo 32% 44% 37% 31% 31%
Rhinoconjunctivitis Medication Score
Durham, page 26 
Grass AIT: mean (median) 1.7 (1.0) 1.7 (0.5) 1.8 (0.8) 2.3 (1.2) 2.4 (1.6)
Placebo: mean (median) 2.7 (2.2) 3.2 (1.7) 3.0 (2.1) 3.2 (2.6) 3.0 (2.1)
Difference in means         
  Absolute [CI 95%] 1.0 [0.6; 1.4] 1.5 [0.8; 2.2] 1.2 [0.5;1.9] 0.9 [0.1; 1.7] 0.6 [-0.1; 1.4] 
  Relative to placebo 38% 45% 40% 29% 20%
  p-value <0.0001 <0.0001 <0.001 0.022 0.114
Difference in medians      
  Absolute 1.2 1.2 1.3 1.4 0.4
  Relative to placebo 55% 73% 60% 52% 21%
*: numbers of participants in the analyses, i.e. all participants providing diary data during the grass pollen season without imputation of data; AIT: allergy 
immunotherapy tablet; ¤: all mean values refer to adjusted means; †: the trial was initially planned to cover a single grass pollen season, and when the trial was extended 
with another 4 years, 195 participants chose not to enroll or were not offered enrolment due to closure of sites. The participants in the extension were a representative 
subset of the population originally included in the trial (see Dahl et al. (11)). 
 505 
506 
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 507 
Table 2: Days with severe symptoms and RQLQ scores during the peaks of the 5 grass pollen seasons covered by the trial 508 
Grass pollen seasons Percent days with severe symptoms, peak season Mean RQLQ scores, peak season 
Placebo Grass AIT Rel. diff. * p-value 
odds 
ratio# Placebo Grass AIT 
Rel. diff. p-value 
Season 1 17 8 52%  <0.0001 0.43 1.8 1.3 25% <0.0001 
Season 2 14 5 63%  <0.0001 0.34 1.4 1.0 29% 0.0003 
Season 3 13 5 61%  <0.0001 0.35 1.4 1.0 32% <0.0001 
Follow-up season 1 16 8 49%  <0.0001 0.47 1.7 1.2 28% 0.0011 
Follow-up season 2 13 6 54%  <0.0001 0.43 1.4 1.1 26% 0.0047 
Days with severe symptoms are defined as a symptom score of 3 in any of the 6 rhinoconjunctivitis symptoms; the peak grass pollen season is defined as the 15 days period with the highest average pollen 
count; RQLQ: rhinoconjunctivitis quality of life questionnaire; *: Rel. diff.=((placebo-grass AIT)/placebo)×100%; #: for risk of having days with severe symptoms in the grass AIT group versus placebo 
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Figure Legends 509 
Figure 1: Weighted rhinoconjunctivitis combined symptom and medication score for the 5 grass 510 
pollen seasons of the trial and averaged over all seasons with relative differences between groups 511 
and CI95%. All relative differences were statistically significant.  512 
 513 
514 
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Figure 2: Weighted rhinoconjunctivitis combined score for grass AIT and placebo as a function of 515 
grass pollen counts (left y-axis).  The grey curve is the cumulated pollen curve (right y-axis). The 516 
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Figure 3: A: Average grass pollen exposures, for participants with diary data on the given day, 521 
during the 5 grass pollen seasons of the trial (2005-2009); B: Linear regression of the relative 522 
difference in the weighted rhinoconjunctivitis combined score against the cumulative grass pollen 523 
counts in the initial 3 weeks of the grass pollen season (S: season, FS: Follow-up season). Lowest 524 
cumulative counts were observed during the second follow-up season (FS2). 525 
 526 
 527 
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Figure 4: The relation between weekly overall rhinoconjunctivitis quality of life (RQLQ) score and 531 
number of weekly days with severe symptoms (-∆-, left axis) and the odds ratio for having days 532 
with severe symptoms in the grass AIT group versus the placebo group (-●-, right axis). Data 533 
included for all 5 seasons of the trial. 534 
 535 
536 
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Figure 5: Change from baseline in specific IgE-blocking factor (A), specific IgG4 (B) and FAP 537 
inhibition (C). Grass pollen seasons are indicated by grey boxes and end of treatment by dotted 538 
lines. The differences between grass AIT and placebo were significant at all assessments. All 539 
samples from years 1-5 were analyzed after the end of the trial. IgG4 measurements for years 1-5 540 
are presented using Phadia CAP RAST. In previous reports, IgG4 analyses were performed using 541 
the Centaur system(33) for which reagents became unavailable for the last year of the trial. 542 
 543 
544 
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Figure 6: Onset of the 4 most common types of adverse events (data from active group only). Note 545 
that “1 day” refers to the same day as treatment was started. None of these types of adverse events 546 
occurred during the 5th year of the trial. 547 
 548 
  549 
Completed season 1 (N = 546) 
Placebo (N = 272) 
Active (N = 274) 
Did not continue in extension (N = 195)* 
Not asked due to closure of sites (N = 68) 
Not wanting to continue (N = 127) 
Continued in extension (Year 2) (N = 351) 
FAS placebo (N = 162) (Provided diary data (N = 144)) 
FAS active (N = 189) (Provided diary data (N = 172)) 
Withdrawals placebo (N = 24) 
Adverse event (N = 2) 
Lack of efficacy (N = 3) 
Other (N = 19) 
Withdrawals active (N = 19) 
Adverse event (N = 1) 
Lack of efficacy (N = 1) 
Other (N = 17) 
Continued in year 3 (N = 308) 
FAS placebo (N = 138) (Provided diary data (N = 127)) 
FAS active (N = 170) (Provided diary data (N = 160)) 
Withdrawals placebo (N = 12) 
Adverse event (N = 1) 
Lack of efficacy (N = 0) 
Other (N = 11) 
Withdrawals active (N = 13) 
Adverse event (N = 1) 
Lack of efficacy (N = 1) 
Other (N = 11) 
Withdrawals placebo (N = 46) 
Adverse event (N = 8) 
Lack of efficacy (N = 1) 
Other (N = 37) 
Withdrawals active (N = 42) 
Adverse event (N = 16) 
Lack of efficacy (N = 0) 
Other (N = 26) 
Enrollment (N = 634) Screening failures (N = 254) 
Full analysis set (Year 1) (N = 634) 
FAS placebo (N = 318) (Providing diary data (N = 286)) 
FAS active (N = 316) (Providing diary data (N = 282)) 
Screened (N = 888) 
Randomization 
Completed the trial (N = 238) 
Placebo (N = 103) 
Active (N = 135) 
Continued in follow-up year 1 (year 4, N = 283) 
FAS placebo (N = 126) (Provided diary data (N = 115)) 
FAS active (N = 157) (Provided diary data (N = 142)) 
Withdrawals placebo (N = 13) 
Adverse event (N = 0) 
Lack of efficacy (N = 1) 
Other (N = 12) 
Withdrawals active (N = 12) 
Adverse event (N = 0) 
Lack of efficacy (N = 0) 
Other (N = 12) 
Continued in follow-up year 2 (year 5, N = 258) 
FAS placebo (N = 113) (Provided diary data (N = 104)) 
FAS active (N = 145) (Provided diary data (N = 137)) 
Withdrawals placebo (N = 10) 
Adverse event (N = 0) 
Lack of efficacy (N = 0) 
Other (N = 10) 
Withdrawals active (N = 10) 
Adverse event (N = 0) 
Lack of efficacy (N = 0) 






FIG E1. Overview of trial participants during the 5th year of the trial. *There were no statistically significant
difference in treatment effect during the grass pollen season 2005 between participants continuing and
participants not continuing in the extension. Other reasons for withdrawal included ‘‘lost to follow-up,’’
‘‘pregnancy,’’ ‘‘withdrawal of consent,’’ ‘‘subject noncompliance,’’ or ‘‘other.’’
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TABLE E1. Rhinoconjunctivitis and asthma symptomatic medications score scheme
Symptomatic medications,
maximum recommended daily dose Score (dose) Maximum score per day*
Rhinoconjunctivitis
Desloratadine: 5 mg/tablet, 1 tablet once daily 6 (per tablet) 6
Olopatadine eye drops: 1.0 mg/mL, 1 drop per eye twice daily 1.5 (per drop) 6
Budesonide nasal spray: 32 mg/puff, 2 puffs per nostril twice daily 1 (per puff) 8
Prednisone: 5 mg/tablet, 10 tablets (50 mg) once daily 1.6 (per tablet) 16
Maximum daily rhinoconjunctivitis medication score 36
Asthma
Salbutamol: 200 mg inhalation, 2 inhalations twice daily 2 (per inhalation) 8
Fluticasone: 250 mg inhalation, 2 inhalations twice daily 2 (per inhalation) 8
Prednisone: 5 mg/tablet, 10 tablets (50 mg) once daily 1.6 (per tablet) 16
Maximum daily asthma medication score 32
*If the recommended dose was exceeded, the actual score was used.
Prednisone counted in the rhinoconjunctivitis score and/or in the asthma score depending on the symptoms.
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TABLE E2. All adverse events leading to trial discontinuation during the 5-year trial period
No. Preferred term Treatment Event start Withdrawal Relation* Severity
Reported during 1st year of the trial
1 Insomnia Grass AIT 15-10-2004 16-11-2004 Possible Mild
2 Edema mouth Grass AIT 29-11-2004 05-01-2005 Probable Moderate
Oral pruritus 29-11-2004 Probable Moderate
3 Throat irritation Grass AIT 01-12-2004 26-01-2005 Probable Moderate
4 Malaise Grass AIT 03-12-2004 04-01-2005 Possible Mild
5 Dysphonia Grass AIT 10-12-2004 14-12-2004 Probable Mild
Oral pruritus 10-12-2004 Probable Severe
Pharyngeal edema 10-12-2004 Probable Severe
6 Nausea Grass AIT 12-12-2004 22-12-2004 Possible Moderate
7 Bronchospasm Grass AIT 12-12-2004 30-12-2004 Probable Mild
8 Cough Grass AIT 13-12-2004 13-12-2004 Probable Moderate
Dyspnea 13-12-2004 Probable Moderate
Edema mouth 13-12-2004 Probable Moderate
Pharyngeal edema 13-12-2004 Probable Moderate
9 Tongue edema Grass AIT 14-12-2004 21-12-2004 Probable Mild
10 Localized edema Grass AIT 15-12-2004 29-12-2004 Unlikely Moderate
Diarrhea 24-12-2004 Unlikely Mild
11 Edema mouth Grass AIT 23-12-2004 27-12-2004 Probable Mild
12 Angioneurotic edema Grass AIT 27-12-2004 30-12-2004 Probable Moderate
13 Oropharyngeal swelling Grass AIT 05-01-2005 07-01-2005 Probable Moderate
14 Eye pruritus Grass AIT 15-12-2004 11-01-2005 Probable Moderate
Oral pain 15-12-2004 Probable Moderate
Oropharyngeal swelling 15-12-2004 Probable Moderate
15 Tongue edema Grass AIT 11-01-2005 11-01-2005 Probable Moderate
16 Vasculitis Grass AIT 20-04-2005 03-05-2005 Possible Mild
17 Pharyngeal edema Placebo 22-11-2004 30-11-2004 Probable Moderate
18 Headache Placebo 07-01-2005 18-01-2005 Possible Moderate
Musculoskeletal stiffness 10-01-2005 Unlikely Mild
19 Cesarean section Placebo 08-09-2005 17-01-2005 Unlikely NA
20 Dyspnea Placebo 30-03-2005 31-03-2005 Unlikely Moderate
21 Subarachnoid hemorrhage Placebo 04-04-2005 04-04-2005 Unlikely Severe
22 Abdominal pain Placebo 03-2005 25-04-2005 Unlikely Mild
Pharyngolaryngeal pain 03-2005 Possible Mild
23 Brain neoplasm Placebo 23-06-2005 28-06-2005 Unlikely Severe
24 Nasal passage irritation Placebo 12-07-2005 10-08-2005 Unlikely Mild
Reported during 2nd year of the trial
25 Arthritis Grass AIT 12-2005 04-01-2006 Possible Mild
26 Headache Placebo 30-09-2005 01-12-2005 Possible Mild
27 Viral infection Placebo 03-04-2006 09-08-2006 Unlikely Moderate
Lymphadenopathy 31-05-2006 Unlikely Moderate
Reported during 3rd year of the trial
28 Asthma Grass AIT 15-06-2007 09-08-2007 Probable Moderate
29 Chlamydial infection (pneumonia) Placebo 03-04-2007 24-04-2007 Unlikely Moderate
*The investigators assessed whether the causality of the adverse event was probable, possible, or unlikely related to the investigational medicinal product.
The participant discontinued because of pregnancy on January 17, 2005. On September 8, 2005, the participant was hospitalized and a cesarean section was performed because of
fetal distress (umbilical cord was compressed). Mother and baby fully recovered and were discharged from hospital on September 15, 2005.
The participant died from the event.
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